Organogenesis Hldgs Q3 2024 Adj. EPS $0.10 Beats $(0.01) Estimate, Sales $115.177M Beat $108.833M Estimate
Organogenesis Hldgs Q3 2024 Adj. EPS $0.10 Beats $(0.01) Estimate, Sales $115.177M Beat $108.833M Estimate
Organogenesis控股2024年第三季调整每股收益$0.10，超过$(0.01)的预期，销售额11517.7万美元，超出预期的10883.3万美元。
Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(0.01) by 1100 percent. This is a 150 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $115.177 million which beat the analyst consensus estimate of $108.833 million by 5.83 percent. This is a 6.12 percent increase over sales of $108.530 million the same period last year.
Organogenesis控股（纳斯达克：ORGO）报告每股盈利为0.10美元，超过分析师共识估计的（0.01）美元1100％。这比去年同期每股盈利0.04美元增长150％。公司报告的季度销售额为11517.7万美元，超过分析师共识估计的10883.3万美元5.83％。这比去年同期的10853万美元销售额增长6.12％。